Sign In
Buy KNSA
$59.49
+2.36 (+4.13%)
At Close: Jun 23, 2026
Is Kiniksa Pharmaceuticals International PLC (KNSA) Overvalued After 3.5% Rally? GF Value Says Overvalued
08:48pm, Monday, 22'nd Jun 2026
On June 22, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares rose 3.5% today, bringing the current price to $57.13. The stock has shown strong perf
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
09:56am, Friday, 19'th Jun 2026
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that
New Strong Buy Stocks for June 18th
06:06am, Thursday, 18'th Jun 2026
TWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 2026.
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
01:02pm, Tuesday, 16'th Jun 2026
Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:22am, Wednesday, 10'th Jun 2026
Kiniksa Pharmaceuticals International, plc (KNSA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41
06:36pm, Friday, 29'th May 2026
On May 29, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares fell 4.8% to $48.41, reflecting a downward trend in the stock's performance over the pa
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
04:01pm, Friday, 29'th May 2026
LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor confere
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation
11:10am, Wednesday, 29'th Apr 2026
Kiniksa Pharmaceuticals continues to outperform, with Arcalyst net sales poised to surpass my previous bullish estimates. Arcalyst captured 18% of the recurrent pericarditis market by end-2025, with a
Breakfast News: Enphase Dips As Solar Demand Dims
07:30am, Wednesday, 29'th Apr 2026
Enphase suffers from weaker U.S. demand, Fiverr jumps on Q1 earnings beat, and more
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
07:10pm, Tuesday, 28'th Apr 2026
Its Arcalyst has been on the market for years, yet it posted strong sales growth in the period. More is to come, apparently, as management raised its net sales guidance for the drug.
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
05:21pm, Tuesday, 28'th Apr 2026
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
09:46am, Tuesday, 28'th Apr 2026
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per s
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
07:30am, Tuesday, 28'th Apr 2026
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million �
Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
04:01pm, Thursday, 23'rd Apr 2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at
What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge
04:56pm, Friday, 17'th Apr 2026
The chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for roughly $309,000 on April 9, 2026. The director reported still holding 27,418 Class A ordinary shares after the transactio
